Literature DB >> 26441555

Editorial: Parkinson's disease: cell vulnerability and disease progression.

Javier Blesa1, Jose L Lanciego2, Jose A Obeso1.   

Abstract

Entities:  

Keywords:  Parkinson disease; dopamine; striatum; substantia nigra; synuclein; vulnerability

Year:  2015        PMID: 26441555      PMCID: PMC4569747          DOI: 10.3389/fnana.2015.00125

Source DB:  PubMed          Journal:  Front Neuroanat        ISSN: 1662-5129            Impact factor:   3.856


× No keyword cloud information.
The hallmark of Parkinson Disease (PD) is the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) and the consequent striatal dopamine (DA) deficiency, although it is well recognized that neurodegeneration in PD goes beyond the SNc. Major advances have occurred in recent years on the molecular and pathophysiological basis of PD, however there remain many questions and unknowns regarding SNc cells vulnerability, and the exact significance of Lewy bodies and alpha-synuclein (α-syn) aggregation process regarding disease onset and progression. This Research Topic discuss the etiopathogenesis of PD, presenting a series of papers that provide up-to-date, state-of-the-art information on molecular and cellular mechanisms involved in the neurodegeneration process, neuroimmune pathways, the role of functional and anatomical organization of the basal ganglia as a factor of neuronal vulnerability, the possibility that PD is a prion disease and the cellular response to α-syn aggregation. Understanding the mechanisms underlying vulnerability of dopaminergic midbrain neurons and how pathology becomes widespread are primary objectives of basic and clinical research in PD. Are dopaminergic and other neurons dying by the same pathogenic mechanisms? Do they all die to the same extent or at the same rate? What are the molecular determinants of susceptibility to the disease? To gain insights into these questions, researchers mainly rely in animal models. Blesa and Przedborski (2014) provide a summary of the current knowledge of in vivo models of PD. Whereas PD can be sporadic, genetic or possibly related with toxic/infectious agents, a differential pattern of cell loss among midbrain dopaminergic neurons is observed regardless of disease etiology suggesting that differential dopaminergic neuron vulnerability does not depend on the factor triggering PD “per se” but on intrinsic properties of these specific cell groups. Here, Brichta and Greengard (2014) provides an update review on the molecular basis underlying differential vulnerability of midbrain dopaminergic neurons in PD. For example, for many years many studies have suggested calbindin (CB) as a marker to distinguish between midbrain dopaminergic neurons with different susceptibility to degeneration in PD. Although CB dopaminergic neurons seem to be less prone to MPTP-induced degeneration, Dopeso-Reyes et al. (2014) clearly demonstrated that these neurons are not giving rise to nigro-striatal projections and indeed CB-ir/TH-ir neurons only originate nigro-extrastriatal projections. This data sustain the presence of a potential imbalance between the nigro-striatal and nigroextrastriatal systems in advanced diseases states. Also, Afonso-Oramas et al. (2014) revealed that midbrain dopaminergic axons are in close apposition to striatal vessels and perivascular astrocytes in rats and monkeys. The relative weight of this “vascular component” within the meso-striatal pathway suggests a role in the pathophysiology of PD. Aging is another major risk factor for developing PD. Rodriguez et al. (2014) reviewed similarities between neurodegeneration in PD and aging. The progressive course of aging and PD could be induced by the same multi-factorial etiology, including astrocytic and microglia alterations, anomalous action of different proteins, mitochondrial disturbances, alterations of the mitophagy or the ubiquitin-proteasome system and oxidative stress. Proteins involved in PD such as α-syn, PINK1 or DJ-1, are also involved in aging. All these mechanisms of degeneration are review here giving an update of the classical pathways, the biochemical and molecular events that mediate DA neuronal vulnerability, and the role of PD-associated gene products in modulating cellular responses to oxidative stress (Blesa et al., 2015). Additionally, Labandeira-García et al. (2014) discuss the role of renin-angiotensin system in oxidative stress, aging and inflammation in the nigrostriatal dopaminergic system. Inflammation is indeed a major characteristic feature of the SNc in PD mainly as a consequence of neuronal death. Herrero et al. (2015) review the role of inflammation and glucocorticoids in PD while Cebrián et al. (2014) review the neuronal MHC-I expression in the SNc and its implications in synaptic function, axonal regeneration in PD and other brain diseases. The dopaminergic neurons of the SNc project primarily to the striatum, but also provide significant innervation of other basal ganglia nuclei and the thalamus. Villalba et al. (2015) discuss evidence for synaptic glutamatergic dysfunction and pathology of cortical and thalamic inputs to the striatum and subthalamic nucleus in models of PD. The altered neuronal firing activity of the basal ganglia and other nuclei contribute largely to parkinsonisms. Galvan et al. (2015) reviewed the current knowledge of the electrophysiologic changes at the single cell level, the level of local populations of neural elements, and the entire basal ganglia-thalamocortical network in PD, and discuss the possible use of this information to optimize treatment approaches. Neuroprotection by endogenous glial cell-derived neurotrophic factor (GDNF) stimulation has been suggested as one of the potential preventive therapies in PD for many years. In this issue d'Anglemont de Tassigny et al. (2015) summarize current knowledge on brain GDNF delivery, homeostasis, and its effects on SNc neurons and discuss the therapeutic potential of endogenous GDNF stimulation in PD. Formation and accumulation of misfolded α-syn aggregates are a central and very hot topic of PD research currently. Several authors review and discuss here the importance of this protein, it's role in different cellular domains (Guardia-Laguarta et al., 2015), the pathophysiological mechanisms connecting α-syn and lysosomal dysfunction in neuronal cell death (Bourdenx et al., 2014), how this protein can undergo a toxic conformational change, spread from cell to cell and from region to region, and initiate the formation of aggregates (Recasens and Dehay, 2014), and its possible relation to other neurodegenerative diseases like progressive supranuclear palsy (Erro Aguirre et al., 2015). While all the features summarized above play a significant role in nigro-striatal neurodegeneration, it is unlikely that the origin of neurodegeneration in PD could be tight to a single pathogenic mechanism, hence the importance of defining markers and features of neuronal vulnerability. Obeso's group introduces here the interesting hypothesis that Parkinson's disease could be related and ultimately be the consequence of human multi-tasking behavior (Hernandez et al., 2015). Thus, the caudal region of the striatum has been associated with habitual behavior, consequently the differential loss of DA from this region provides the pathophysiological substrate for the early impairment of automatic movements (walking, writing…) and probably increased functional demand during multiple and simultaneous tasks performance. In sum, understanding the mechanisms responsible for intrinsic SNc neuronal vulnerability is mandatory to progress in stopping neurodegeneration in PD. We trust that this Research Topic will spark new ideas and foster further advances in PD.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  16 in total

Review 1.  Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update.

Authors:  Lars Brichta; Paul Greengard
Journal:  Front Neuroanat       Date:  2014-12-15       Impact factor: 3.856

2.  Calbindin content and differential vulnerability of midbrain efferent dopaminergic neurons in macaques.

Authors:  Iria G Dopeso-Reyes; Alberto J Rico; Elvira Roda; Salvador Sierra; Diego Pignataro; Maria Lanz; Diego Sucunza; Luis Chang-Azancot; Jose L Lanciego
Journal:  Front Neuroanat       Date:  2014-12-03       Impact factor: 3.856

Review 3.  Inflammation in Parkinson's disease: role of glucocorticoids.

Authors:  María-Trinidad Herrero; Cristina Estrada; Layal Maatouk; Sheela Vyas
Journal:  Front Neuroanat       Date:  2015-04-02       Impact factor: 3.856

Review 4.  Alpha-synuclein spreading in Parkinson's disease.

Authors:  Ariadna Recasens; Benjamin Dehay
Journal:  Front Neuroanat       Date:  2014-12-18       Impact factor: 3.856

Review 5.  The degeneration and replacement of dopamine cells in Parkinson's disease: the role of aging.

Authors:  Manuel Rodriguez; Ingrid Morales; Clara Rodriguez-Sabate; Alberto Sanchez; Rafael Castro; Jose Miguel Brito; Magdalena Sabate
Journal:  Front Neuroanat       Date:  2014-08-07       Impact factor: 3.856

Review 6.  Novel subcellular localization for α-synuclein: possible functional consequences.

Authors:  Cristina Guardia-Laguarta; Estela Area-Gomez; Eric A Schon; Serge Przedborski
Journal:  Front Neuroanat       Date:  2015-02-23       Impact factor: 3.856

Review 7.  Parkinson's disease: animal models and dopaminergic cell vulnerability.

Authors:  Javier Blesa; Serge Przedborski
Journal:  Front Neuroanat       Date:  2014-12-15       Impact factor: 3.856

Review 8.  Oxidative stress and Parkinson's disease.

Authors:  Javier Blesa; Ines Trigo-Damas; Anna Quiroga-Varela; Vernice R Jackson-Lewis
Journal:  Front Neuroanat       Date:  2015-07-08       Impact factor: 3.856

Review 9.  Brain renin-angiotensin system and dopaminergic cell vulnerability.

Authors:  Jose L Labandeira-García; Pablo Garrido-Gil; Jannette Rodriguez-Pallares; Rita Valenzuela; Ana Borrajo; Ana I Rodríguez-Perez
Journal:  Front Neuroanat       Date:  2014-07-08       Impact factor: 3.856

Review 10.  GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's disease.

Authors:  Xavier d'Anglemont de Tassigny; Alberto Pascual; José López-Barneo
Journal:  Front Neuroanat       Date:  2015-02-13       Impact factor: 3.856

View more
  4 in total

1.  Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson's disease.

Authors:  Hui-Fang Liu; Philip Wing-Lok Ho; Gideon Chi-Ting Leung; Colin Siu-Chi Lam; Shirley Yin-Yu Pang; Lingfei Li; Michelle Hiu-Wai Kung; David Boyer Ramsden; Shu-Leong Ho
Journal:  Sci Rep       Date:  2017-01-18       Impact factor: 4.379

Review 2.  Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff.

Authors:  Heiko Braak; Kelly Del Tredici
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

3.  A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's disease.

Authors:  Debleena Guin; Manish Kumar Mishra; Puneet Talwar; Chitra Rawat; Suman S Kushwaha; Shrikant Kukreti; Ritushree Kukreti
Journal:  BMC Med Genomics       Date:  2017-09-19       Impact factor: 3.063

4.  Computer Aided Written Character Feature Extraction in Progressive Supranuclear Palsy and Parkinson's Disease.

Authors:  Paula Stępień; Jacek Kawa; Emilia J Sitek; Dariusz Wieczorek; Rafał Sikorski; Magda Dąbrowska; Jarosław Sławek; Ewa Pietka
Journal:  Sensors (Basel)       Date:  2022-02-21       Impact factor: 3.576

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.